Drug Combinations Useful for Prevention of Restenosis

Abstract

The current invention comprises an approach to solving the clinical problem of restenosis, which involves the administration of combinations of drugs to patients undergoing PTCA or stent implantation. In one embodiment of the invention, an antiproliferative agent such as rapamycin, vincristine or taxol is administered in combination with the anti-inflammatory agent, dexamethasone, to patients systemically, either subcutaneously or intravenously. In another embodiment of the invention, the antiproliferative and anti-inflammatory agents are bound in a single formulation to the surface of a stent by means of incorporation within either a biodegradeable or biostable polymeric coating. Alternatively, such drug combinations could be incorporated into a stent constructed with a grooved reservoir.

1 - 15 . (canceled) 
     
     
         16 . In combination:
 a catheter for the delivery of drugs to a blood vessel lumen of a patient; and   a therapeutic dosage amount of the combination of an anti-proliferative agent for inhibiting smooth muscle cell growth comprising rapamycin or an analogue thereof and an anti-inflammatory agent for inhibiting smooth muscle growth, both said agents contained in therapeutic dosage amounts.   
     
     
         17 . The combination of  claim 16  wherein the anti-inflammatory agent comprises dexamethasone. 
     
     
         18 . The combination of  claim 16  wherein the combination of at least two agents further includes a growth factor or cytokine signal transduction inhibitor. 
     
     
         19 . The combination of  claim 16  wherein the combination of at least two agents further includes a tyrosine kinase inhibitor. 
     
     
         20 . The combination of  claim 16  wherein the combination of at least two agents further includes an inhibitor of extracellular matrix synthesis. 
     
     
         21 . The combination of  claim 20  wherein the inhibitor of extracellular matrix synthesis comprises halofuginone and the anti-proliferative agent is taken from a group consisting of rapamycin, taxol, or vincristine.